Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) provides access to the company’s official U.S. regulatory disclosures as a commercial-stage biopharmaceutical and medical dermatology issuer. These documents, filed with the Securities and Exchange Commission, give detailed insight into Arcutis’ financial performance, governance, and progress in developing and commercializing therapies for immune-mediated dermatological diseases and conditions.
Key filings include annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe product revenue from the ZORYVE (roflumilast) franchise, research and development expenses related to atopic dermatitis, plaque psoriasis, seborrheic dermatitis, and pipeline programs, as well as selling, general, and administrative costs tied to commercialization. These reports also summarize risk factors, intellectual property, and other information relevant to Arcutis’ pharmaceutical preparation manufacturing activities.
Current reports on Form 8-K document material events such as quarterly and year-to-date financial results, strategic updates, and changes in the composition of the board of directors. For example, recent 8-K filings describe the release of financial results for specific quarters and the retirement and appointment of directors, including details of compensation arrangements and consulting agreements. Such filings help investors track governance developments and corporate actions in real time.
Investors interested in executive and director compensation, equity awards, and governance policies can review proxy statements and related exhibits, while those monitoring capital structure and financing activities can examine notes in periodic reports and any registration statements or prospectus supplements that may be filed. Filings also confirm that Arcutis’ common stock is registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Global Select Market under the symbol ARQT.
On this page, Stock Titan pairs Arcutis’ raw SEC filings with AI-powered summaries that highlight key points from lengthy documents, such as revenue trends for ZORYVE products, major R&D milestones, and notable risk factor updates. Users can quickly scan AI-generated overviews of Forms 10-K and 10-Q, then drill into the full text for deeper analysis. Real-time ingestion from EDGAR ensures that new 8-Ks, periodic reports, and exhibits appear promptly, while structured views of ownership and transaction data make it easier to follow equity awards and other reportable items disclosed in Arcutis’ filings.
Arcutis Biotherapeutics filed a shelf registration statement to register multiple securities for potential future offerings. The prospectus covers common stock, preferred stock, debt securities, warrants, purchase contracts and units and permits selling securityholders to resell shares. The company states it will not receive proceeds from selling securityholders’ resales.
Arcutis Biotherapeutics (ARQT) is a commercial-stage dermatology-focused biopharmaceutical company centered on its topical PDE4 franchise ZORYVE and its biologic candidate ARQ-234. The company now markets four ZORYVE formulations across plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp/body psoriasis in the United States and Canada, with multiple pediatric label expansions and additional sNDAs planned.
Arcutis estimates an actively prescription-treated U.S. market of about 17 million topical patients across its core diseases and aims to position ZORYVE as a chronic, non-steroidal alternative to topical steroids, expanding from dermatology into primary care and pediatrics. Its strategy also includes life-cycle indication expansion (such as hidradenitis suppurativa and vitiligo), international licensing deals in Japan and Asia, and advancement of ARQ-234, a CD200R agonist being prepared for Phase 1 in atopic dermatitis with broader inflammatory potential.
Arcutis Biotherapeutics reported strong growth and a profitable fourth quarter 2025 while raising 2026 sales guidance. Q4 2025 net product revenue for ZORYVE was $127.5 million, up 84% year over year and 29% sequentially, driving total Q4 revenue to $129.5 million versus $71.4 million a year earlier.
Full-year 2025 net product revenue for ZORYVE reached $372.1 million, a 123% increase over 2024, with total revenue of $376.1 million. The company generated Q4 net income of $17.4 million, compared with a $10.8 million loss in Q4 2024, and narrowed its full-year net loss to $16.1 million from $140.0 million.
Arcutis produced $26.2 million of operating cash flow in Q4 and ended 2025 with $221.3 million in cash, cash equivalents, restricted cash, and marketable securities. It raised 2026 net product revenue guidance to a range of $480 million to $495 million and highlighted positive clinical progress and pipeline advancement for ZORYVE and ARQ-234.
Rubric Capital Management and David Rosen report passive ownership of
The ownership percentage is based on 122,492,192 shares outstanding as of October 22, 2025, as disclosed in Arcutis’s Form 10-Q for the quarter ended September 30, 2025. The filers certify the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Prudential Financial, Inc. reported beneficial ownership of 7,079,926 shares of Arcutis Biotherapeutics, Inc. common stock, representing 5.7% of the class as of 12/31/2025.
Prudential has sole voting and dispositive power over 45,000 shares and shared voting power over 6,381,022 shares, with shared dispositive power over 7,034,926 shares. The position is held through subsidiaries including Jennison Associates LLC, The Prudential Insurance Company of America, and Quantitative Solutions LLC. Prudential states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Arcutis.
Arcutis Biotherapeutics executive Masaru Matsuda reported multiple stock sales. On February 2, 2026, he sold blocks of Arcutis common stock at weighted average prices of $24.97 to $25.63, in several transactions disclosed in the filing.
The filing explains that one sale was made to cover tax withholding obligations tied to vesting restricted stock units granted on January 12, 2024. All reported transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on June 5, 2025. Following these trades, Matsuda beneficially owned 110,003 shares of Arcutis common stock in direct form as the company’s SVP, General Counsel and Corporate Secretary.
Arcutis Biotherapeutics executive Patrick Burnett, Executive Vice President and Chief Medical Officer, reported selling Arcutis common stock in two transactions. On February 2, 2026, he sold 3,675 shares at a weighted average price of $25.4984 to cover tax withholding tied to vesting restricted stock units. On February 4, 2026, he sold 9,794 shares at a weighted average price of $25.8064. Both transactions were executed under a Rule 10b5-1 trading plan adopted on December 12, 2024, with a plan end date of February 27, 2026. After these sales, Burnett directly beneficially owned 80,651 shares of Arcutis common stock.
Arcutis Biotherapeutics President and CEO Todd Watanabe, who also serves as a director, sold 19,833 shares of common stock on February 2, 2026 at a weighted average price of $25.4984 per share. The sale was made to cover tax withholding obligations arising from the vesting of previously granted restricted stock units.
After this transaction, Watanabe beneficially owned 721,306 common shares directly. Additional indirect holdings are reported through several entities, including trusts and an LLC, with reported positions of 25,410 shares, 25,410 shares, 57,358 shares, and 124,956 shares, where he disclaims beneficial ownership beyond his pecuniary interest.
Arcutis Biotherapeutics SVP CFO Latha Vairavan reported a small insider sale tied to equity compensation. On February 2, 2026, she sold 1,320 shares of common stock at a weighted average price of $25.4984 per share. According to the footnotes, the sale was made solely to cover tax withholding obligations arising from the vesting of previously granted restricted stock units. Following this transaction, she beneficially owns 63,607 shares of Arcutis common stock directly.
Arcutis Biotherapeutics director Howard G. Welgus sold shares under a pre-set trading plan. On February 2, 2026, he sold 10,000 shares of Arcutis common stock at a weighted average price of $25.0483 per share pursuant to a Rule 10b5-1 plan adopted on March 11, 2025. After this planned sale, he beneficially owns 59,744 shares of common stock directly.